Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelor
Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelor
复制标题
DOI：
10.3109/09537104.2015.1095874
复制
发表时间：
2016-01-01
期刊：
影响因子：
3.3
通讯作者：
Delle-Karth, Georg
中科院分区：
文献类型：
--
作者：
Siller-Matula, Jolanta M.;Akca, Betul;Delle-Karth, Georg
本研究的目的是评估接受普拉格雷和替格瑞洛治疗的患者血小板反应性值的分布。这项前瞻性观察性研究纳入了200名接受普拉格雷或替格瑞治疗的患者。在普拉格雷或替格瑞洛治疗维持期，经二磷酸腺苷（ADP）刺激后，采用多电极聚集法测定血小板聚集。只有3%的普拉格雷组患者和2%的替格瑞洛组研究参与者具有高的治疗血小板反应性（HTPR）。大多数患者表现出较低的治疗血小板反应性（LTPR；普拉格雷：69%；替格瑞洛：64%）。普拉格雷与替格瑞治疗患者的药效学效果相似：普拉格雷组adp诱导血小板聚集的中位水平为15U（四分位数范围IQR 9-21U），替格瑞洛组为17U（四分位数范围IQR 8-24U） （p=0.370）。总之，我们的研究表明，在普拉格雷和替格瑞洛治疗下，adp诱导的血小板聚集存在一定程度的变异性。
The aim of this study was to evaluate the distribution of platelet reactivity values in patients treated with prasugrel and ticagrelor. This prospective observational study enrolled 200 patients treated with prasugrel or ticagrelor. Platelet aggregation was determined by multiple electrode aggregometry after stimulation with adenosine diphosphate (ADP) in the maintenance phase of treatment with prasugrel or ticagrelor. Only 3% of patients in the prasugrel group and 2% of study participants in the ticagrelor group had high on treatment platelet reactivity (HTPR). The majority of patients displayed low on treatment platelet reactivity (LTPR; prasugrel: 69%; ticagrelor: 64%). The pharmacodynamic effect was similar in patients treated with prasugrel and ticagrelor: the median level of ADP-induced platelet aggregation was 15U (interquartile range IQR 9-21U) under prasugrel treatment and 17U (IQR 8-24U) under ticagrelor treatment (p=0.370). In conclusion, our study suggests that there is some degree of variability in ADP-induced platelet aggregation under treatment with prasugrel and ticagrelor.